SGMO vs. ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, VNDA, LXRX, CDXS, and ACHV
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Codexis (CDXS), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Sangamo Therapeutics (NASDAQ:SGMO) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
In the previous week, Zenas Biopharma had 20 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 22 mentions for Zenas Biopharma and 2 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 1.79 beat Zenas Biopharma's score of -0.01 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Zenas Biopharma has lower revenue, but higher earnings than Sangamo Therapeutics. Zenas Biopharma is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Zenas Biopharma has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. Zenas Biopharma's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics presently has a consensus price target of $4.50, suggesting a potential upside of 773.28%. Zenas Biopharma has a consensus price target of $36.67, suggesting a potential upside of 207.09%. Given Sangamo Therapeutics' higher probable upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Zenas Biopharma.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Zenas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Sangamo Therapeutics received 453 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 62.60% of users gave Sangamo Therapeutics an outperform vote.
Summary
Zenas Biopharma beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy SGMO Stock Free SGMO Stock Alerts